Anixa Biosciences (ANIX) Assets (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Assets came in at $14.9 million in Q2 2026, down 12.44% YoY from $17.0 million in Q2 2025, and down 7.56% on a QoQ basis from $16.1 million in Q4 2025.
Anixa Biosciences (ANIX) Assets (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Assets data on file, last reported at $14.9 million in Q2 2026.
- Quarterly Assets fell 12.44% year-over-year to $14.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $14.9 million (down 12.44% YoY) and the FY2025 annual result came in at $16.1 million, down 25.52% from the prior year.
- Assets eased to $14.9 million in Q2 2026, from $16.1 million in the prior quarter.
- In the past five years, Assets ranged from a high of $35.2 million in Q1 2022 to a low of $14.9 million in Q2 2026.
- A 5-year average of $24.6 million and a median of $25.4 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets surged 141.28% — and 2025, when it plunged 30.29%.
- Tracing ANIX's Assets over 5 years: stood at $30.4 million in 2022, then decreased by 16.08% to $25.5 million in 2023, then declined by 15.4% to $21.6 million in 2024, then decreased by 25.52% to $16.1 million in 2025, then slipped by 7.56% to $14.9 million in 2026.
- The last three Assets figures came in at $14.9 million (Q2 2026), $16.1 million (Q4 2025), and $17.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | 14.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 14.87 Mn |
| Oct 31, 2025 | 16.08 Mn |
| Jul 31, 2025 | 17.65 Mn |
| Apr 30, 2025 | 16.98 Mn |
| Jan 31, 2025 | 18.91 Mn |
| Oct 31, 2024 | 21.59 Mn |
| Jul 31, 2024 | 22.91 Mn |
| Apr 30, 2024 | 24.36 Mn |
| Jan 31, 2024 | 25.37 Mn |
| Oct 31, 2023 | 25.52 Mn |
| Jul 31, 2023 | 26.58 Mn |
| Apr 30, 2023 | 27.60 Mn |
| Jan 31, 2023 | 28.31 Mn |
| Oct 31, 2022 | 30.41 Mn |
| Jul 31, 2022 | 32.56 Mn |
| Apr 30, 2022 | 32.80 Mn |
| Jan 31, 2022 | 35.24 Mn |
| Oct 31, 2021 | 36.26 Mn |
| Jul 31, 2021 | 37.06 Mn |
| Apr 30, 2021 | 38.50 Mn |